All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Glucagon
Therapeutic Area: Endocrinology Product Name: Ogluo
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2021
Details:
European Commission (EC) has approved Ogluo™ (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Glucagon
Therapeutic Area: Endocrinology Product Name: Gvoke
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Megapharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 22, 2020
Details:
Megapharm will be responsible for registration and marketing of Gvoke in Israel and the Palestinian Authority, and named patient services supply. Xeris will manufacture, supply, and will take care of the quality assurance and control, regulatory support, and maintenance of IP.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Levothyroxine Sodium
Therapeutic Area: Endocrinology Product Name: Thyquidity
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Vertice Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 17, 2020
Details:
Vertice will make a specified quarterly payment to MannKind to defray the costs of the additional promotional activity and will pay MannKind royalties on gross profit resulting from all sales of Thyquidity.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Leuprolide Acetate
Therapeutic Area: Endocrinology Product Name: Fensolvi
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2020
Details:
The study evaluated 45-mg subcutaneous leuprolide acetate administered at a 6-month interval in 64 GnRHa-naïve children with CPP. Fensolvi effectively suppressed reproductive hormones and stopped or caused regression of pubertal progression.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Insulin Lispro
Therapeutic Area: Endocrinology Product Name: Lyumjev
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 07, 2020
Details:
Companies will partner to promote Lyumjev, Lilly's new rapid-acting insulin, with Dexcom G6 Continuous Glucose Monitoring (CGM), highlighting the benefits of using each.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hydrocortisone
Therapeutic Area: Endocrinology Product Name: Alkindi Sprinkle
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
ALKINDI SPRINKLE is the first and only FDA-approved granular hydrocortisone formulation for adrenocortical insufficiency specifically designed for children.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Endocrinology Product Name: Viagra
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Farmalider SA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 29, 2020
Details:
Aspargo’s Sildenafil Oral Spray is an oral liquid suspension of sildenafil citrate administered via a spray pump that dispenses 12.5 mg of sildenafil citrate per push of the pump (referred to as ASP-001) or via an individual single liquid unit dispensing 100 mg per unit.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dulaglutide
Therapeutic Area: Endocrinology Product Name: Trulicity
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Details:
The approval expands the label of once-weekly Trulicity to include 3.0 mg and 4.5 mg doses based on data from AWARD-11. The phase 3 trial showed the additional doses led to further benefits in A1C and body weight reduction when compared to Trulicity 1.5 mg.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Insulin
Therapeutic Area: Endocrinology Product Name: MiniMed 770G
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
